Tag: Antipseudomonal agents

In 2023, the Clinical and Laboratory Standards Institute removed gentamicin as a recommended treatment for *Pseudomonas aeruginosa*, solidifying a shift away from this traditional antibiotic. The primary reasons address the core question: Why is gentamicin no longer used for Pseudomonas?

The CDC notes that *Pseudomonas aeruginosa* is one of the most common bacteria associated with nosocomial (hospital-acquired) infections and is notorious for its formidable intrinsic and acquired resistance mechanisms. Understanding **what antibiotics are Pseudomonas susceptible to** requires careful consideration of this pathogen's resistance profiles and localized epidemiology.